Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
Herrington WG., Preiss D., Haynes R., von Eynatten M., Staplin N., Hauske SJ., George JT., Green JB., Landray MJ., Baigent C., Wanner C.
[This corrects the article DOI: 10.1093/ckj/sfy090.].